Emese Filka

Irinotecan Treatment for Recurrent Malignant Glioma Using an Every-3-Week Regimen

T. Cloughesy, F. Kabbinavar, H. Friedman, 2002, American journal of clinical oncology.

Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.

Albert Lai, Whitney B Pope, Stacey Green, 2018, International journal of radiation oncology, biology, physics.

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.

Paul S Mischel, Albert Lai, Phioanh L Nghiemphu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Prospective Blinded Study of the Predictive Value of an Extreme Drug Resistance Assay in Patients Receiving CPT-11 for Recurrent Glioma

T. Cloughesy, R. Parker, R. Mehta, 2004, Journal of Neuro-Oncology.

Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.

T. Cloughesy, L. Liau, P. Mischel, 2008, International journal of radiation oncology, biology, physics.

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every‐3‐week regimen

T. Cloughesy, F. Kabbinavar, H. Friedman, 2003, Cancer.